Replagal (agalsidase alfa) / Samaritan Pharma, Takeda  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
NCT02930655: A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease

Completed
1b
14
Europe
Lucerastat, ACT-434964, Enzyme replacement therapy (ERT), Fabrazyme, Replagal
Idorsia Pharmaceuticals Ltd.
Fabry Disease
02/16
02/16
NCT00357786: An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease

Completed
1
3
US
Replagal agalsidase alfa, Replagal
National Institute of Neurological Disorders and Stroke (NINDS)
Fabry Disease
12/08
 

Download Options